Skip to contentpdufa.bio

axatilimab

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

axatilimab is an Incyte Corp, Syndax Pharmaceuticals Inc program in chronic GVHD. Its next catalyst is a Readout in Q1 2027.

INCY catalyst hub · SNDX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: Chronic GVHD; Newly diagnosed (frontline) chronic GVHD. Sponsor: Incyte Corp, Syndax Pharmaceuticals Inc (INCY, SNDX). We track 3 catalyst events for this program: 3 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027SNDXReadout · Sep 2027INCYReadout · Q4 2028SNDX

Specialist biotech funds holding INCY, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors30,762,652$3.73 billionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is axatilimab's next FDA decision or readout?

The next tracked catalyst for axatilimab is a Readout in Q1 2027.

What happened at axatilimab's most recent FDA decision?

No FDA decision for axatilimab is in our archive yet.

What is axatilimab used for?

In our records axatilimab is under review or in development for Chronic GVHD; Newly diagnosed (frontline) chronic GVHD.

Who makes axatilimab?

Incyte Corp, Syndax Pharmaceuticals Inc (INCY, SNDX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.